

Disclosures

Personal Commercial (37)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Alkem Metabolics	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Alynlyam Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Amgen Inc.	Research/Research Grants ‡ My employer Glasgow University is paid by Amgen Inc. for my involvement as a Executive/Steering Committee member in the COSMIC-HF and GALACTIC-HF trials (no personal payment).	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Other - My employer Glasgow University is paid by AstraZeneca for my involvement as Executive committee/PI for DAPA-HF, DELIVER & DETERMINE trials	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Bayer Healthcare Pharmaceuticals	Other - My employer Glasgow University is paid by Bayer for my involvement as Steering Committee member for PANACHE & FINEART-HF trials.	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Blue Ocean Scientific Solutions Ltd.	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Boehringer Ingelheim Pharmaceuticals, Inc	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Bristol-Myers Squibb Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Canadian Medical and Surgical Knowledge	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Cardurion	Other - My employer Glasgow University is paid by Cardurion for my involvement as Advisory Board member about development of a PDE-9 inhibitor in heart failure.	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Cytokinetics	Other - My employer Glasgow University is paid by Cytokinetics for my involvement as Steering Committee member for ATOMIC-HF, COSMIC-HF & GALACTIC-HF trials.	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Emcure Pharmaceuticals Ltd.	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Eris Lifesciences	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
European Academy of CME	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
George Clinical PTY Ltd.	Data Safety Monitoring Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Global Clinical Trial Partners Ltd. (GCTP)	Other - Director	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
GSK	Other - My employer Glasgow University is paid by GSK for my involvement as (HARMONY Trial co-PI) daprodustat (ASCEND-CKD Trial EC)	Significant (>= \$5,000)	Prevention
Hikma Pharmaceuticals	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Imagica Health	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Intas Pharmacueticals	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Ionis Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
J.B. Chemicals & Pharmaceuticals Ltd.	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
KBP Biosciences	Other - My employer, Glasgow University, has been paid by KBP Biosciences for my time spent scientific advisor to company to help guide clinical development in cardio-renal disease, inflammation & infection.	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Lupin Pharmaceuticals, Inc	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Novartis Corporation	Research/Research Grants ‡ My employer Glasgow University is paid by Novartis for my involvement as (Executive/Steering Committee/PI for ATMOSPHERE, PARADIGM-HF, PARAGON-HF, PARADISE-MI, PERSPECTIVE & PARACHUTE-HF trials)	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
ProAdWise Communications	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Radcliffe Cardiology	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Regeneron Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
River 2 Renal Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Sun Pharmaceuticals	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
The Corpus	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Translation Research Group	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Translational Medicine Academy	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/9/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/9/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/9/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/9/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.